Matthew E. B. Dixon

Closest collaborators

The 10 strongest of 10 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Niraj Jaysukh Gusani · 4 shared papers, 2021–2022 · strength 0.71
   • Paper Undertreatment of Pancreatic Cancer: The Intersection of Bias, Biology, and Geography. DOI 10.1016/j.soc.2021.07.006↗
   • Paper Undertreatment of Pancreatic Cancer: Role of Surgical Pathology. DOI 10.1245/s10434-020-09043-y↗
   • Paper Pathologic upstaging in resected pancreatic adenocarcinoma: Risk factors and impact on survival. DOI 10.1002/jso.26481↗
2. Chan Shen · 4 shared papers, 2021–2024 · strength 0.68
   • Paper Disparities in Surgical Treatment of Resectable Pancreatic Adenocarcinoma at Minority Serving Hospitals. DOI 10.1016/j.jss.2023.09.066↗
   • Paper Undertreatment of Pancreatic Cancer: Role of Surgical Pathology. DOI 10.1245/s10434-020-09043-y↗
   • Paper Pathologic upstaging in resected pancreatic adenocarcinoma: Risk factors and impact on survival. DOI 10.1002/jso.26481↗
3. June S. Peng · 4 shared papers, 2021–2024 · strength 0.68
   • Paper Disparities in Surgical Treatment of Resectable Pancreatic Adenocarcinoma at Minority Serving Hospitals. DOI 10.1016/j.jss.2023.09.066↗
   • Paper Undertreatment of Pancreatic Cancer: Role of Surgical Pathology. DOI 10.1245/s10434-020-09043-y↗
   • Paper Pathologic upstaging in resected pancreatic adenocarcinoma: Risk factors and impact on survival. DOI 10.1002/jso.26481↗
4. Elizabeth Josephine Olecki · 4 shared papers, 2021–2024 · strength 0.68
   • Paper Disparities in Surgical Treatment of Resectable Pancreatic Adenocarcinoma at Minority Serving Hospitals. DOI 10.1016/j.jss.2023.09.066↗
   • Paper Undertreatment of Pancreatic Cancer: Role of Surgical Pathology. DOI 10.1245/s10434-020-09043-y↗
   • Paper Pathologic upstaging in resected pancreatic adenocarcinoma: Risk factors and impact on survival. DOI 10.1002/jso.26481↗
5. Madeline B. Torres · 3 shared papers, 2021–2022 · strength 0.56
   • Paper Undertreatment of Pancreatic Cancer: The Intersection of Bias, Biology, and Geography. DOI 10.1016/j.soc.2021.07.006↗
   • Paper Pathologic upstaging in resected pancreatic adenocarcinoma: Risk factors and impact on survival. DOI 10.1002/jso.26481↗
   • Paper Adjuvant Chemotherapy After Neoadjuvant Chemotherapy for Pancreatic Cancer is Associated with Improved Survival for Pat… DOI 10.1245/s10434-020-09546-8↗
6. Daniel Jonathan Kagedan · 2 shared papers, 2016 · strength 0.10
   • Paper The association of adjuvant therapy with survival at the population level following pancreatic adenocarcinoma resection. DOI 10.1016/j.hpb.2015.12.005↗
   • Paper Predictors of adjuvant treatment for pancreatic adenocarcinoma at the population level. DOI 10.3747/co.23.3205↗
7. Nicole Mittmann · 2 shared papers, 2016 · strength 0.10
   • Paper The association of adjuvant therapy with survival at the population level following pancreatic adenocarcinoma resection. DOI 10.1016/j.hpb.2015.12.005↗
   • Paper Predictors of adjuvant treatment for pancreatic adenocarcinoma at the population level. DOI 10.3747/co.23.3205↗
8. Natalie G. Coburn · 2 shared papers, 2016 · strength 0.10
   • Paper The association of adjuvant therapy with survival at the population level following pancreatic adenocarcinoma resection. DOI 10.1016/j.hpb.2015.12.005↗
   • Paper Predictors of adjuvant treatment for pancreatic adenocarcinoma at the population level. DOI 10.3747/co.23.3205↗
9. R.S. Raju · 2 shared papers, 2016 · strength 0.10
   • Paper The association of adjuvant therapy with survival at the population level following pancreatic adenocarcinoma resection. DOI 10.1016/j.hpb.2015.12.005↗
   • Paper Predictors of adjuvant treatment for pancreatic adenocarcinoma at the population level. DOI 10.3747/co.23.3205↗
10. Qing Li · 1 shared paper, 2016 · strength 0.05
    • Paper The association of adjuvant therapy with survival at the population level following pancreatic adenocarcinoma resection. DOI 10.1016/j.hpb.2015.12.005↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.